Pancreatic Cancer | Oncology Today with Dr Neil Love: PARP Inhibition in the Management of Pancreatic Cancer Edition

published 1 month ago by Dr Neil Love

Featuring an interview with Dr Kim Reiss Binder on recent advances in the use of PARP inhibitors in pancreatic cancer, including the following topics: PARP inhibitors in pancreatic cancer — Kim Reiss Binder, MD (00:00) Case: A man in his late 50s with metastatic pancreatic adenocarcinoma and a germline BRCA2 mutation attains a good response to maintenance olaparib after treatment with platinum-based chemotherapy (32:40) Case: A man in his early 50s with metastatic pancreatic adenocarcinoma and a PALB2 mutation receives maintenance rucaparib on a clinical trial (37:54) Case: A woman in her late 50s with metastatic pancreatic adenocarcinoma experiences a complete response to the combination of niraparib and ipilimumab on the Parpvax trial after receiving chemotherapy (41:59) CME information and select publications

more episodes from Research To Practice | Oncology Videos